Individualizing anaemia therapy - Wikidata - wikimedia - TriplyDB

Individualizing anaemia therapy

Individualizing anaemia therapy

http://www.wikidata.org/entity/Q40329273

about

Individualizing anaemia therapy

http://www.wikidata.org/entity/Q40329273

description

2010 nî lūn-bûn

@nan

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

2010年论文

@zh

2010年论文

@zh-cn

name

Individualizing anaemia therapy

@en

type

label

Individualizing anaemia therapy

@en

prefLabel

Individualizing anaemia therapy

@en

P1433

Q40329273-E90F8C87-AB5B-4478-9BB7-D7B9960ABB49

P1476

Q40329273-982E97BD-4E99-412C-9A25-BCE2DE6F7E2C

P2093

Q40329273-C7731F8F-4A44-4935-9C6D-AB6DD68B6023

P2860

Q40329273-0AC45465-C772-47E6-A9CA-3E9371DFB8DF

Q40329273-0F0340FD-A9AD-4B1A-B340-F29845091118

Q40329273-0F36D231-3DDF-4139-B50B-6DCF6A1D49A3

Q40329273-11C8AE7C-CFEC-48EA-9FCD-EE6C554DD1C6

Q40329273-158D0CAE-F9F3-4290-A21A-E2CACBF1B15C

Q40329273-18D04E28-2C7B-42F2-9E93-3EABE1256809

Q40329273-1A9E37B4-56DA-45E9-AE4B-C39086FB1317

Q40329273-1E388DCF-EC95-4BBC-95E7-8FCCA5651D22

Q40329273-2266D62B-492C-4DA3-A4E2-6A661E483525

Q40329273-239E0BEA-20E8-4186-91C7-5FD404A4D2FD

P304

Q40329273-3F597CAA-A2F1-4BA6-B22F-E3E956656460

P31

Q40329273-AB5EE3ED-824D-47A8-879B-6CD102F1B2EE

P356

Q40329273-C5A3EDC0-6040-46E2-A9E1-18142D41850F

P433

Q40329273-842B002B-4E13-4591-9AEC-A702B1F69034

P478

Q40329273-71203CBC-C197-4954-A105-F590E7447770

P577

Q40329273-8E260FCC-B544-4D9D-B5F0-F8A36FAC6FEF

P5875

Q40329273-0461B022-11C8-4682-B901-27B93F4B686E

P698

Q40329273-25E154E7-D72E-4530-A231-64623FC63478

P932

Q40329273-D9A5E4B7-6A18-4C2D-9C6C-9CE09996602C

P356

P1433

P1476

Individualizing anaemia therapy

@en

P2093

Angel L M de Francisco

http://www.w3.org/2001/XMLSchema#string

P2860

Haemoglobin and haematocrit targets for the anaemia of chronic kidney disease

Recombinant human erythropoietin for chronic renal failure anaemia in pre-dialysis patients

Frequency of administration of recombinant human erythropoietin for anaemia of end-stage renal disease in dialysis patients

Normalization of hemoglobin level in patients with chronic kidney disease and anemia

Interpretation and review of health-related quality of life data in CKD patients receiving treatment for anemia.

Secondary analysis of the CHOIR trial epoetin-alpha dose and achieved hemoglobin outcomes.

Target haemoglobin to aim for with erythropoiesis-stimulating agents: a position statement by ERBP following publication of the Trial to reduce cardiovascular events with Aranesp therapy (TREAT) study.

Erythropoietin requirements increase following hospitalization in end-stage renal disease patients.

Hemoglobin variability does not predict mortality in European hemodialysis patients.

The long-term effects of recombinant human erythropoietin on the cardiovascular system.

P304

519-526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/NDTPLUS/SFQ164

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P577

2010-09-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

274431073

http://www.w3.org/2001/XMLSchema#string

P698

25949459

http://www.w3.org/2001/XMLSchema#string

P932

4421434

http://www.w3.org/2001/XMLSchema#string